Advanced search×

Developing an effective medication soldier readiness process.

Roger A RA Gallup and James N JN Masterson

Mil Med 172(7):713-7 (2007) PMID 17691683

With the ever high operation tempo that our Armed Forces experience, it is imperative that military providers understand their soldiers' medication needs and how to ensure that those medications are properly processed by the supporting military pharmacy. Without a definitive plan, the surgeons responsible for soldiers' health will fail. This article outlines the experiences of the 4th Infantry Division and Darnall Army Community Hospital while preparing the 4th Infantry Division soldiers for deployment in support of Operation Iraqi Freedom 2005-2007. It details some important statistics that medical planners and unit surgeons can use when preparing their soldiers for deployment. Finally, we outline the lessons learned from this latest deployment and suggest components of an effective medication soldier readiness process.

Version: za2963e q8za5 q8zb5 q8zc4 q8zdf q8zea q8zf8 q8zg5

Similar articles you may find interesting…

  1. The cost effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK.
    Anthony J Batty, Ryan N Hansen, and Sean D Sullivan

    J Med Econ (2013) PMID 23647483

    At 2 years, treatment with onabotulinumtoxinA was associated with an increase in costs of £1,367 and an increase in QALYs of 0.1 compared to placebo, resulting in an incremental cost-effectiveness ratio (ICER) of £15,028. Treatment with onabotulinumtoxinA reduced headache days by an estimated 38 d...
  2. Real-life effectiveness and tolerability of rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: The EMBRAC...
    Serge Gauthier, Alain Robillard, and on behalf of the EMBRACE investigators

    Curr Med Res Opin (2013) PMID 23647369

    Rivastigmine transdermal patch is effective in maintaining cognitive function over 18 months of treatment in patients with mild-to-moderate AD. The safety profile was comparable to the data in the Canadian product monograph. Lack of a comparator group is a potential limitation of the study....
  3. Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for r...
    Mark Cascione, Daniel Wynn, and Kevin McCague

    J Med Econ (2013) PMID 23647445

    Results of the EPOC study are anticipated in early 2013 and will inform treatment selection by providing patient-centered data on therapy switch to fingolimod or standard-of-care DMTs. Trial Registration: ClinicalTrials.gov NCT01216072....